摘要
目的探讨缬沙坦抑制C反应蛋白(CRP)的效果与机制及其在动脉粥样硬化临床中的价值。方法对本院2009～2012年收治的100例动脉粥样硬化患者平均分为治疗组和对照组,治疗组采用缬沙坦治疗。分别测量患者治疗前外周血血清中的CRP和治疗后血清中的CRP,对比两组血清中治疗前和治疗后CRP含量的变化。结果治疗组治疗前和治疗后血清中CRP的含量分别为4.87、2.58 mg/L,变化较大,治疗前后差异有统计学意义(P<0.05)。对照组治疗前后血清中的CRP含量分别为4.84、3.78 mg/L,变化较大,治疗前后差异有统计学意义(P<0.05)。治疗组与对照组治疗后差异无统计学意义(P>0.05)。结论动脉粥样硬化可能与炎症有关,缬沙坦可以抑制动脉粥样患者炎性因子的释放,从而降低CRP的水平。CRP作为一种动脉粥样硬化检测的指标具有可行性。
Objective To explore the effects and mechanism of valsartan on inhibiting CRP and its clinical value of atherosclerosis. Methods One hundred atherosclerosis patients addmitted from 2009 to 2012 were divided into treatment group and control group, the treatment group were given valsartan. The plasma CRP concentration of the two groups at pretreat and post-treat were measured and were compared, respectively. Results The CRP concentration of treatment group at pre-treat and post-treat was 4.87 mg/L and 2.58 mg/L, respectively, the difference was significant （P 〈 0.05）. The control group was 4.84 mg/L and 3.78 mg/L, the difference was significant （P 〈 0.05）. The difference between treatment group and con- trol group at post-treat was not significant （P 〉 0.05）. Conclusion Atherosclerosis may be relate to inflamation, and valsartan can inhibit the release of inflamator and decrease the levels of CRP. As a marker of atherosclerosis, CRP is feasible.
出处
《中国当代医药》
2012年第19期88-88,90,共2页
China Modern Medicine
